论文部分内容阅读
急性心肌梗塞（心梗）１１０６例，２～４周后随机分为对照、阿替洛尔和依那普利三组。随访时间中值１９个月，对照组生存率较其它两个用药组有较明显的下降趋势。阿替洛尔或依那普利可以减少心脏猝死率，在２年４个月后阿替洛尔组与对照组差异有显著性（Ｐ＜０．０５）。依那普利或阿替洛尔可以提高左室射血分数，治疗过程中射血分数的增加率，依那普利组是对照组的２８．５倍（三组间差异有显著性，Ｐ＜０．０５）。三组的再梗塞率相近，与对照组比较，用药组未能降低再梗率。结论是阿替洛尔或依那普利对我国患者有二级预防心梗后主要并发症的作用。
1106 cases of acute myocardial infarction (MI) were randomly divided into control, atenolol and enalapril groups after 2 to 4 weeks. The median follow-up time of 19 months, the survival rate of the control group compared with the other two treatment groups have a significant downward trend. Atenolol or enalapril can reduce the rate of sudden cardiac death in atenolol group and control group after 2 years and 4 months, the difference was significant (P <0.05). Enalapril or atenolol can increase the left ventricular ejection fraction, the rate of increase in ejection fraction during treatment, 28.5 times that of the enalapril group (significant difference between the three groups, P <0.05). Re-infarction rates were similar in the three groups, compared with the control group, the medication group failed to reduce the rate of reinfarction. The conclusion is that atenolol or enalapril has a secondary effect on preventing major complications after myocardial infarction in our patients.